Aktis Oncology, Inc.

AKTS chart

Aktis Oncology, Inc. news

• AIM ImmunoTech Inc. (AIM) Seasonal returns chart

  Yahoo Finance UK · Nov 6, 1:22 AM EST

• AKTS Q2 2026 Earnings: Per-Share Loss Edges Past Estimates as Shares Decline - Preliminary Results

  https://www.dars.gov.et/ · Nov 5, 1:31 PM EST

• Aktis Oncology (NASDAQ:AKTS) Is In A Good Position To Deliver On Growth Plans

  Moomoo · Nov 3, 5:03 AM EST

• Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3

  Yahoo Finance · Oct 1, 8:00 AM EDT

• Aktis Oncology to Present at Upcoming September Investor Conferences

  Yahoo Finance · Sep 9, 8:00 AM EDT

• Aktis Oncology Seen Advancing Targeted Radiation-Based Cancer Drugs, Wedbush Says

  Yahoo Finance · Aug 19, 11:42 AM EDT

• Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play

  247wallst.com · Aug 19, 8:10 AM EDT

• Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026

  Yahoo Finance · Aug 13, 4:01 PM EDT

• Aktis Oncology to Present at the Jefferies Global Healthcare Conference

  Yahoo Finance · May 27, 4:05 PM EDT

• A Look At Aktis Oncology (AKTS) Valuation After Recent Share Price Rebound

  Yahoo Finance · May 25, 3:05 PM EDT

• Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors

  Yahoo Finance · May 21, 5:21 PM EDT

• Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company

  fool.com · May 13, 4:30 PM EDT

Aktis Oncology, Inc. key financials

Calendar-year figures as reported to the SEC in XBRL filings.

Recent SEC filings

• 10-Q10-Q2026-08-13
• 8-K8-K2026-08-13
• 10-Q10-Q2026-05-11
• 8-K8-K2026-05-11
• 8-K8-K2026-04-16
• 8-K8-K2026-03-30
• 10-K10-K2026-03-30
• 8-K8-K2026-01-12
• S-1S-12025-12-19

About Aktis Oncology, Inc.

Ticker

AKTS (Nasdaq)

Industry

Pharmaceutical Preparations

Headquarters

Boston, MA

Incorporated in

DE

Fiscal year end

December 31

SEC CIK

2035832

Frequently asked questions